27 results
6-K
EX-99.2
IFRX
InflaRx N.V.
5 Jun 24
InflaRx Hosts R&D Event Highlighting the Promise of INF904
5:07pm
Current understanding of the C5a/C5aR1 biology Prof. Dr. Jörg Köhl Why target C5aR1 in the immuno-dermatologic space?
Zhang and Köhl Expert Rev
424B5
IFRX
InflaRx N.V.
13 Apr 23
Prospectus supplement for primary offering
8:48am
expert advice on those matters.
Notice to Prospective Investors in Canada
The securities offered in this prospectus may be sold only to purchasers … Suppurativa Severity Score 4, or IHS4, which also scores all inflammatory lesions and has been developed by an international expert group to score severity
424B5
IFRX
InflaRx N.V.
11 Apr 23
Prospectus supplement for primary offering
4:11pm
, and, if necessary, seek expert advice on those matters.
Notice to Prospective Investors in Canada
The securities offered in this prospectus may be sold only … Suppurativa Severity Score 4, or IHS4, which also scores all inflammatory lesions and has been developed by an international expert group to score
6-K
EX-99.1
0lf2wff7tbg9bv4xb2
5 Nov 21
Current report (foreign)
7:30am
6-K
EX-99.1
p0pxcc jak9wp
5 Aug 21
Current report (foreign)
8:23am
6-K
EX-99.1
ynela3 o9zbnpkw
12 May 21
Current report (foreign)
4:30pm
424B5
0qjqz5n9
26 Feb 21
Prospectus supplement for primary offering
5:10pm
424B5
zoz bfknxs
24 Feb 21
Prospectus supplement for primary offering
5:16pm
6-K
ym857jcqrad dr5ane
24 Feb 21
Current report (foreign)
4:16pm
6-K
EX-99.2
qkfmapi
29 Oct 20
Current report (foreign)
7:05am
6-K
EX-99.1
kh3kc1sk0ak
29 Oct 20
Current report (foreign)
7:05am
424B5
yptwqeeu
20 Jul 20
Prospectus supplement for primary offering
9:21am
F-3
6bqszifzo2i
8 Jul 20
Shelf registration (foreign)
12:00am
6-K
EX-99.1
9g1fspf3vn78f8qh
30 Jun 20
Current report (foreign)
6:38am
6-K
EX-99.1
vos2aqn9hu na
29 Apr 20
InflaRx Reports Full Year 2019 Financial & Operating Results
8:00am